… , rivaroxaban, apixaban, and edoxaban, are poised to replace warfarin for treatment of the
majority of patients with venous thromboembolism (VTE). With a rapid onset of action and the …

Venous thromboembolism (VTE), the third most frequent acute cardiovascular syndrome, is
associated with a considerable disease burden which continues to grow along with the …

… thrombosis, proximal This review focuses on the long-term treatment of leg deep vein
thrombosis (DVT) and pulmonary embolism (PE) and does not include arm DVT or venous …

… By simplifying long-term anticoagulant therapy and … thrombosis. Licensed for stroke prevention
in atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolism (…

… Treatment of superficial venous thrombosis (SVT) has … well as concomitant deep venous
thrombosis. Traditional therapies … The incidence of deep venous thrombosis has been reported …

… Venous thromboembolism (VTE) is a common vascular condition. New medications are …
Management of deep vein thrombosis (DVT) and pulmonary embolism (PE) has evolved with the …

… and treatment of venous thromboembolism (VTE)-pulmonary embolism (PE) and deep venous
thrombosis (… Evolving treatment modalities have reduced the mortality due to PE to ~2%. …

… potential strengths and weaknesses, iii) describes the results of clinical trials with these new
drugs, and iv) identifies the evolving role of new anticoagulants in the management of VTE. …

… In summary, there were dramatic increases and reductions in the use of diagnostic tests
between 1979 and 1999 that reflect the evolving paradigms of care for venous thromboembolism…

… Conclusion: A new paradigm for treating VTE is evolving based on the results of recent
research to incorporate the use of emerging antithrombotic therapies in the acute treatment …